Home
overview

The conference listed on this page was held in 2006. For information on the 2010 conference go to www.smi-online.co.uk/2010europricing.asp  

European Pharmaceutical Pricing & Reimbursement Conference 2010

  


It is essential for pharmaceutical companies to understand fully the market environment and the principles governing pricing in these markets.  The pricing of new products is crucial.  If the price is set too high, the product may fail to gain reimbursement, if the price is too low, profitability will be reduced.

SMi's 12th Annual European Pharmaceutical Pricing and Reimbursement Conference in Germany is a must attend event.  This year the agenda will include detailed updates of the key regulatory developments and an in-depth analysis of the issues surrounding pricing and reimbursement including the latest trends and the future of parallel trade.  The conference will include country-specific case studies from the following markets - UK, Germany, Italy, France and Spain. We also use examples from the US and Canada along with SEE countries as a contrast to the big 5 markets.

Speakers at this event include:

  • Dr Andrea Rappagliosi, Vice President, Corporate Health Policy & Government Relations, Serono International
  • Dr Rainer Walenta, Director, Global Pricing & Reimbursement, Solvay Pharmaceuticals
  • Julian Mount, Senior Director, European Trade, Pfizer
  • Kathy Feegel, Sr. Director, State Government Affairs, Amgen
  • Peter Conway, Director, Market Access & Reimbursement, Wyeth Europa
  • Dr Slawomir Chomik, Area Director, Central and Eastern Europe, Solvay Pharmaceuticals
  • Dr Ann-Katrin Gonschior, Market Access and Reimbursement, Sanofi-Aventis
  • Dr Antoni Gilabert Perramon, Director, Pharmaceutical Care & Complimentary Benefits, Catalan Health Service
Key issues addressed at the event include
  • PRICING SYSTEMS IN THE EU: How do they affect orphan drugs?
  • EUROPE & THE GLOBAL PHARMACEUTICAL MARKET: Discover how pricing and reimbursement systems have developed around the world
  • RECENT TRENDS ON PRICING: How are pricing systems evolving in Europe and how can this benefit you?
  • COMMON MISCONCEPTIONS ABOUT PRICING AND REIMBURSEMENT IN EUROPE: How can these misdirect strategies?
  • KEY INDUSTRY PERSONNEL: Meet leaders in the field, make valuable contacts and learn from their experience and expertise



Click here to view hotel directions and reservation information.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Andrea Rappagliosi

Andrea Rappagliosi, Vice President, Corporate Health Policy & Government Relations, Serono International S A

9:10 DEVELOPMENTS IN PPRS

Gary Johnson

Gary Johnson, Managing Director, Inpharmation Ltd

  • Application developments for branded generic drugs
  • The use of evidence-based-medicine in the National Health Service (NHS)
  • Increasing levels of generic prescribing and its impact on pricing in the UK market
  • How do PPRS encourage research and development?
  • How are the updated regulations affecting overall prices and reimbursement in the UK?
  • 9:50 THE IMPACT OF HEALTH ECONOMIC ASSESSMENT ON ORPHAN DRUGS

    Andrea Rappagliosi

    Andrea Rappagliosi, Vice President, Corporate Health Policy & Government Relations, Serono International S A

  • Clinical and regulatory issues in developing orphan drugs
  • Health Technology Assessment (HTA) and orphan drugs: the issues at stake
  • Developing new models to measure the value of orphan drugs
  • 10:30 Morning Coffee

    11:00 Panel Discussion

    Andrea Rappagliosi

    Andrea Rappagliosi, Vice President, Corporate Health Policy & Government Relations, Serono International S A

  • The new EU accession markets – minimising the threat of parallel trade in an enlarged EU
  • Identifying potential growth segments in the new EU markets
  • The emerging role of the Health Technology Assessment in the EU – a threat or an opportunity?
  • 11:40 TAKING THE GUESS WORK OUT OF GENERIC PRICING

    Charles Joynson

    Charles Joynson, Chief Executive Officer, Wavedata

  • Traditional methods are based on guesswork
  • Poor forecasting is expensive
  • Generic declines are pattern based
  • These patterns can be predicted
  • WaveData's new product PROfesy can this
  • Similar declines apply in other industries   
  • 12:20 Networking Lunch

    13:50 LINKS BETWEEN ECONOMIC REGULATION AND R&D IN THE PHARMACEUTICAL INDUSTRY

    Jorge Mestre-Ferrandiz

    Jorge Mestre-Ferrandiz, Senior Economist, Office Of Health Economics

  • How do these regulatory mechanisms affect price, volume and/or expenditure on medicines?
  • What are the links between economic regulation and R&D in the pharmaceutical market?
  • 14:30 TECHNOLOGY ASSESSMENT IN GERMANY

    Ann-Katrin Gonschior

    Ann-Katrin Gonschior, Market Access & Reimbursement, Sanofi-Aventis Deutschland GmbH

  • How is IQWiG assessing the benefit of pharmaceutical products?
  • How do IQWiG appraisals affect pricing and reimbursement?
  • Future scenarios and international context
  • 15:10 Afternoon Tea

    15:40 THE NEW AVWG REGULATIONS

    Rainer Walenta

    Rainer Walenta, Director, Global Pricing and Reimbursement, Solvay Pharmaceuticals G Mb H

  • New developments in regulations
  • Drug containment in Germany
  • Plans for healthcare reform
  • How will the new AVWG regulations create €1.3 Billion in savings per year?
  • 16:20 COMMON MISCONCEPTIONS ABOUT PRICING AND REIMBURSEMENT

    Chris Sutton

    Chris Sutton, Senior Principal, IMS Pricing and Reimbursement, IMS Health

  • Some common assumptions and beliefs
  • How can misconceptions be challenged?
  • What evidence or data can be used?
  • How do misconceptions misdirect strategy?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Alain Vernot

    Alain Vernot, Managing Director, APM HEALTH Europe

    9:10 NEW PRICING AND REIMBURSEMENT PROCESSES

    Fabrizio Gianfrate

    Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara

  • Recent changes in pricing policy
  • The new national formulation: what is the criteria for reference pricing?
  • Increased regional control
  • Problems raised
  • Pharmacoeconomics in Italy
  • 9:50 HOW IS REIMBURSEMENT USED IN THE ITALIAN MARKET?

    Lorenzo Terranova

    Lorenzo Terranova, Head, Economics Office, Farmindustria

  • How does reimbursement in Italy occur?
  • Price fixing
  • What are the difficulties in gaining reimbursement?
  • What are the advantages and disadvantages of the Italian reimbursement system?
  • 10:30 Morning Coffee

    11:00 REGULATION OF FRENCH DRUG PRICING

  • The pricing and reimbursement approval process in France
  • The committees involved in the pricing and licensing process
  • The ASMR (improvement of medical benefit) assessment - how does this affect pricing decisions?
  • The SMR (therapeutic value) assessment and its impact on reimbursement in France
  • Nathalie Drouillet-Burban

    Nathalie Drouillet-Burban, Trading Director, OCP Repartition

    Maurice Dantes

    Maurice Dantes, Director of Corporate Purchasing, Celesio AG

    11:40 THE IMPACT OF ELECTRONIC PRESCRIPTION

    Antoni Gilabert

    Antoni Gilabert, Director Pharmaceutical Care & Complementary Benefits, Catalan Health Service

  • The potentialities for pharmacists and chemists
  • Improving patient care and fraud preventions
  • The impact on the pharmaceutical market and supply chain
  • 12:20 Networking Lunch

    13:50 PATIENT INTERACTION WITH PAYORS

    Peter Conway

    Peter Conway, Market Access and Reimbursement, Wyeth

  • What to patients want from their reimbursement systems
  • What to patients get from the reimbursement systems
  • What relationships to payors have currently with patients in their systems
  • How those relationships develop in the next 5 years
  • What is the role of physicians and healthcare professionals?
  • 14:30 EUROPEAN UNION: AN INTERNAL MARKET FOR PHARMACEUTICALS?

    Luis González Vaqué

    Luis González Vaqué, Advisor, European Commission

  • What obstacles are there to the free movement of goods?
  • Parallel imports: the ECJ's case law and the commission's communication
  • Industrial property in perspective
  • The situation in the 10 new member states and the candidate countries
  • 15:10 Afternoon Tea

    15:40 PRICING AND REIMBURSEMENT IN SEE COUNTRIES

    Slawomir Chomik

    Slawomir Chomik, Area Director, Central Europe, Solvay

  • How has EU expansion affected the pricing policies in SEE countries?
  • What are the main pricing and reimbursement differences in this part of Europe?
  • What are the benefits of this system?
  • Is there a black market for drugs and will this affect safety in the rest of Europe?
  • 16:20 CANADA AND THE UNITED STATES

    Kathy Feegel

    Kathy Feegel, Senior Director, State Government Affairs, Amgen

  • What are the current ‘real’ issues between the US and Canada over parallel trade?
  • Price controls and reimbursement issues
  • How do political issues and legislation affect the pharmaceutical industry?
  • What is the future of trade in pharmaceuticals between Canada and the US?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Pharmaceutical Pricing Megatrends
    Workshop

    Pharmaceutical Pricing Megatrends

    Steigenberger Frankfurter Hof
    3rd November 2006
    Frankfurt am Main, Germany

    Steigenberger Frankfurter Hof

    Am Kaiserplatz
    60311
    Frankfurt am Main
    Germany

    Steigenberger Frankfurter Hof

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.